Next-Generation
Protein Conjugation

At CatenaBio, we envision a future where therapeutics are limited only by imagination.

Breakthrough Protein Conjugation

CatenaBio’s CysTyr® platform utilizes the novel Catenase® enzyme, which catalyzes the formation of our proprietary C-Y Bond® using only native amino acids.

Our approach eliminates the current size and complexity constraints that restrict molecule connections. This allows attachment of multiple different cargoes to a protein, delivering new therapeutic modalities.

All this is accomplished with greater speed, stability, selectivity, and scalability than current approaches.

Explore the science
A molecule with an inactivated n- or c-terminal tyrosine.

Our approach eliminates the current size and complexity constraints that restrict molecule connections. This allows attachment of multiple different cargoes to a protein, delivering new therapeutic modalities.

All this is accomplished with greater speed, stability, selectivity, and scalability than current approaches.

Explore the science
A molecule with an inactivated n- or c-terminal tyrosine.
A molecule conjugated with a second molecule using the C-Y bond

Exceptional Minds
Exceptional Innovation

Our team has been instrumental in advancing medical research. Our technology was developed in the same halls where CRISPR was born, a connection that fuels our passion for pushing the boundaries of scientific discovery.

Meet our team

Catena Biosciences Expands Executive Leadership Team, Appoints Saurabh Johri as Chief Business Officer and Rick Kendall as Chief Scientific Officer

July 27, 2023  |  Berkeley, CA